C2N Diagnostics and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to study how Parkinson’s disease and similar neurodegenerative conditions overlap with Alzheimer’s disease. With a grant in the amount of more than $1.5 million from MJFF, researchers at C2N will identify and…

Low-dose fosgonimeton (ATH-1017), an investigational small molecule, may have cognitive benefits for people with Parkinson’s disease-related dementia or dementia with Lewy bodies, according to recent data from a clinical trial. The small exploratory Phase 2 study, called SHAPE (NCT04831281), tested the safety and efficacy of fosgonimeton given once…

Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…

Annovis Bio has been given the go-ahead by the U.S. Food and Drug Administration (FDA) to begin a Phase 3 clinical trial to test buntanetap (ANVS401) as an oral therapy for early-stage Parkinson’s disease. “With this FDA notice in hand, we are thrilled to…

A blood test that assesses how the activity of a group of enzymes, called P450s, changes when they are blocked could be useful for diagnosing Parkinson’s disease in early stages, according to a new study. “Effective diagnostic systems and biomarkers for patients without subjective motor symptoms have not yet been…

Injecting acidic nanoparticles into mice in a model of Parkinson’s disease protected against nerve cell loss and restored the ability of lysosomes, cell compartments responsible for breaking down excess or damaged proteins, to work as they should, a research team reported. “Our results support lysosomal re-acidification as a disease-modifying strategy for…

The U.S. Food and Drug Administration (FDA) has given positive feedback to Annovis Bio’s plans to start two Phase 3 clinical trials of buntanetap (ANVS401) as an oral therapy for early- and late-stage Parkinson’s disease. The feedback followed a review of data from a Phase 2 clinical trial showing significant…

Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in people with early-stage Parkinson’s disease, according to a press release. This follows the acceptance of Green Valley‘s investigational new drug (IND) application by the U.S Food and Drug…

Along with my fellow columnists at Parkinson’s News Today, I have previously written about the benefits of music and dance for those with Parkinson’s disease or other neurological conditions. Research has shown that dancing to music may slow the progression of both motor and non-motor symptoms by affecting gait,…

Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among Parkinson’s disease patients in a Phase 2a clinical trial. Annovis Bio, the company developing ANVS401, is now planning to meet with the U.S. Food and Drug Administration (FDA) to discuss possibly initiating larger Phase 3 studies. “We…